荣昌生物制药（烟台）股份有限公司（09995）8月12日公告称，公司董事会将于2026年8月24日（星期一）召开会议，审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及其刊发事宜。
根据公告，董事会现由9名成员组成，包括执行董事王威东、房健民、温庆凯、房艺及王玉晓；非执行董事王荔强；独立非执行董事宋希亮、黄国滨及陈云金。
上述会议结果及相关中期业绩报告一经董事会通过，预计将按规定及时对外发布。公司提醒投资者关注后续公告。
本公告由董事长兼执行董事王威东代表董事会签署，公告日期为2026年8月12日。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.